SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending amidst intense market volatility driven by escalating geopolitical tensions surrounding discussions of tariffs linked to Greenland. Community sentiment is sharply divided, with some investors anticipating a significant market downturn due to uncertainty and potential European retaliation, while others expect a swift "buy the dip" rebound, referencing past instances where tariff-related drops quickly reversed.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to heightened geopolitical tensions stemming from discussions between the U.S. and European nations regarding potential tariffs and Greenland. This situation has driven a risk-off sentiment across the crypto market, sparking community debates about Bitcoin's role as a safe haven asset, even as some investors see current price movements as a chance to accumulate.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top discussion point as investors anticipate its upcoming earnings report, which coincides with ongoing speculation surrounding a potential Warner Bros. Discovery acquisition and the company's new Monthly Active Viewers metric. The community remains sharply divided, with some expecting a significant upward move from oversold conditions, while others foresee further downside due to deal uncertainty and high volatility.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending significantly as renewed geopolitical tensions intensify, primarily driven by discussions around potential US tariffs on European countries concerning Greenland. This has sparked community debate regarding gold's role as a safe-haven asset, with many anticipating further upside amid broader uncertainty and concerns over currency debasement, while others caution about an overextended rally. The ongoing criticism of the Federal Reserve's independence adds another layer of market uncertainty supporting precious metals.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is a trending topic, driven by robust Q3 revenue and an upwardly revised outlook. Further excitement stems from its new Vision AI, showcased at CES, expanding its innovative voice and multimodal AI platform. Community discussion is vibrant, with many anticipating a short squeeze due to high short interest, while others vocalize concerns about perceived price manipulation as the stock navigates its consolidation.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to strong anticipation ahead of its upcoming earnings report, coupled with widespread speculation about major government foundry contracts and a potential significant client win for its advanced chip manufacturing. The community is actively discussing Intel's potential comeback and its perceived undervaluation compared to industry peers, driven by the broader narrative of domestic semiconductor manufacturing and surging demand for AI and server chips.

United States Commodity Funds LLC - United States Natural Gas Fund

United States Natural Gas Fund, LP

United States Natural Gas Fund ($UNG) is trending as an intensifying Arctic air invasion across large parts of the US is forecast to drive a significant surge in heating demand. The community is buzzing about a potential short squeeze, given extreme short interest and the sudden shift to frigid weather, though acknowledging the commodity's notorious volatility. This immediate weather catalyst is compounded by emerging long-term demand narratives surrounding AI data centers.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as a high-conviction meme on the Injective blockchain, currently energized by a governance proposal aiming to significantly boost $INJ's deflation rate and strong institutional interest. The community widely views $NONJA as a resilient and "unruggable" asset, boasting burned liquidity and an active base, making it the go-to leveraged play for Injective's anticipated growth during the next market cycle. Many believe $NONJA is well-positioned for outsized returns as the underlying chain continues to mature and gain recognition.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending following recent international approvals for its cancer immunotherapies, notably in Saudi Arabia for lung cancer, alongside updated positive clinical study results. The community is enthusiastically discussing the potential of Anktiva to revolutionize cancer treatment and is vocal about perceived US FDA delays, which is fueling significant speculation around a short squeeze. Investors are expressing strong optimism regarding Dr. Soon-Shiong's strategic vision and the company's considerable growth trajectory.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is actively trending following its recent registered direct offering, which initially prompted price fluctuations but is now seen by many as a strategic move by institutional investors. Community discussion highlights the stock's extremely low float and high short interest, driving speculation for a potential short squeeze. Bullish sentiment is further fueled by the company's expansion into the burgeoning prediction markets sector through new partnerships, indicating significant long-term growth prospects.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside

Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025.

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement 

Shares of Verve Therapeutics, Inc. (VERV) rocketed 75% in pre-market on Tuesday after Eli Lilly and Company (LLY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-verve-therapeutics-advance-one-time-treatments">announced</a> its intent to acquire the company for up to $1.3 billion.Verve is developing gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD), such as low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a), through treatments that may only need to be given once in a lifetime.Under the terms of the deal, Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones. The aggregate value of the deal is approximately $1.3 billion.The upfront purchase price of $10.50 represents a premium of over 67% to Verve’s closing price on Monday.The transaction is expected to close in the third quarter, subject to customary closing conditions.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/VERV">VERV</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1262/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_18_59_AM_png_4e0f45260c.webp" alt="VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1262" height="134"><figcaption>VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the offer seems low.<stembedurl>https://stocktwits.com/XavierXV/message/618132279</stembedurl>Another user believes that the offer is ‘terrible’ for long-term shareholders while being great news for those who bought it recently.<stembedurl>https://stocktwits.com/PensionPulse/message/618129981</stembedurl> Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY</a> stayed unchanged within ‘neutral’ territory, coupled with ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:1268/142;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_21_01_AM_png_80a8da75d9.webp" alt="LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1268" height="142"><figcaption>LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure>Both LLY and VERV stocks are up by about 4% this year.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-expects-tesla-deliveries-to-dip-further-in-2025/chlYvypRRTv">Wells Fargo Expects Tesla Deliveries To Dip Further In 2025, But Retail Says Downward Trend Is Over</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’

Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.

Verve Therapeutics Stock Rockets 76% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B

Equity

Eli Lilly is in late-stage talks to purchase Verve Therapeutics in a transaction that could total $1.3 billion, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/53d021c9-d15f-4471-86ef-e9abfc3ae7db">report</a> by the Financial Times.Verve Therapeutics surged 74.8% after hours to $10.96 following takeover speculation, while Eli Lilly slipped 1.4% to $807.58 during regular trade.The deal features an upfront payment of nearly $1 billion and an additional $300 million, contingent upon clinical results, which would double Verve Therapeutics' current market value to $559 million.Verve is advancing gene-editing treatments for high cholesterol and&nbsp;has disclosed positive Phase 1 findings for its primary drug candidate.&nbsp;The company already has a partnership with Eli Lilly.If completed, the deal would extend Lilly’s focus on early-stage innovation rather than commercial-stage assets — a strategy backed by its financial strength from diabetes and obesity blockbusters Mounjaro and Zepbound, projected to generate over $30 billion this year.Lilly’s potential move comes amid renewed biopharma dealmaking after a subdued period.Recent deals include Sanofi’s $9.5 billion tie-up with Blueprint Medicines and Bristol Myers Squibb’s $11.1 billion collaboration with BioNTech.&nbsp;The Verve deal will reportedly be announced later this week, barring any last-minute changes.On Stocktwits, retail sentiment for Eli Lilly was ‘neutral’ with ‘normal’ message volume, while Verve Therapeutics saw ‘extremely bullish’ sentiment amid ‘extremely high’ message volume.Eli Lilly’s stock has risen 3.8% so far in 2025, while Verve Therapeutics’ stock has gained 4.3%For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks

The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies.

Eli Lilly close to buying gene editing firm Verve for $1.3 bln- FT

Investing.com-- Eli Lilly and Company (NYSE:LLY) is in advanced talks to buy gene editing start-up  Verve Therapeutics  Inc (NASDAQ:VERV), the Financial Times reported on Monday, as the world’s biggest drugmaker seeks to increase its pipeline of experimental drugs. 

What Makes Verve Therapeutics (VERV) a New Buy Stock

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

VERV
Verve Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VERV News

VERVVerve Therapeutics Inc